Filokyp 60 mg Injection
PDF Leaflet Revision Date: 15 May 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of relapsed and refractory multiple myeloma after at least 2 prior therapies.
Dosage (summary)
IV infusion, starting at 20 mg/mu00b2, increasing to 27 mg/mu00b2 if tolerated, administered twice weekly.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Not recommended during pregnancy; contraindicated in breastfeeding.
Key Drug Interactions
- Caution with P-glycoprotein substrates
- Antiviral prophylaxis for herpes zoster
Contraindications
- Hypersensitivity to carfilzomib
- Breastfeeding
Common side effects
- Anaemia
- Thrombocytopenia
- Neutropenia
- Nausea
- Fatigue
Counselling Points
- Monitor for signs of cardiac issues
- Ensure adequate hydration
- Use contraception during treatment
Serious warnings
- Cardiac failure
- Pulmonary toxicity
- Hypertension
- Acute renal failure
Important Disclaimer
The Filokyp 60 mg Injection professional information leaflet below is the property of Glenmark Pharmaceuticals South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
